Oral CRAC channel inhibitors

CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. Several highly selective candidates with attractive pharmacokinetic properties that are consistent with once-daily oral dosing are currently in pre-clinical toxicology testing and in confirmatory studies in several animal models including chronic pancreatitis.

Scroll to Top